



Suggested Formula	Spironolactone 5 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 493v6
-------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Spironolactone, USP	0.500	g				
Propylene Glycol, USP	2.0	mL				
Medisca Oral Mix (Flavoured Suspending Vehicle)	48.0	mL				
Medisca Oral Mix (Flavoured Suspending Vehicle)	q.s. to 100.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible): *Spironolactone, Propylene Glycol*

Hygroscopic (protect from moisture whenever possible): *Propylene Glycol*

Oxygen sensitive (protect from oxygen whenever possible): *Spironolactone*

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Spirolactone 5 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 493v6
-------------------	---	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : ____	Processing Error	Qty. to measure
Spirolactone, USP §	0.500	g			
Propylene Glycol, USP §	2.0	mL			
Medisca Oral Mix (Flavoured Suspending Vehicle)	48.0	mL			
Medisca Oral Mix (Flavoured Suspending Vehicle)	q.s. to 100.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction	
1.	<p><u>Powder-liquid preparation:</u></p> <p>A. Triturate the Spirolactone to form a fine, homogeneous powder.</p> <p>B. Levigate the fine, homogeneous powder blend (Step 1A) with the Propylene Glycol.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
2.	<p><u>Medium integration:</u></p> <p>A. Incrementally add the homogeneous liquid-like dispersion (Step 1B) to the Oral Mix (Flavoured Suspending Vehicle) (48.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
3.	<p><u>Filling to volume:</u></p> <p>A. Add additional Oral Mix (Flavoured Suspending Vehicle) to the above mixture to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>



Suggested Formula	Spironolactone 5 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 493v6
-------------------	---	-----	-------------

4.	<p><u>Product transfer:</u></p> <p>A. Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>
----	---

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	90 days at 4°C or 25°C, based on available stability studies through Medisca*.	Packaging Requirements	Amber Glass or Amber PET Bottle.	
	<p>*Suggested BUD is based on the exact execution of the indicated ingredient list, quantities and procedures listed within this formulation.</p> <p>Note: <i>This data is provided for informational purposes only, representing the results of a study of the product stability with various active pharmaceutical ingredients. It does not serve, and may not be construed, as a representation or guarantee of product performance. In all cases the practitioner is advised to consult recognized pharmaceutical compendia and other recognized sources for product formulation and other product characteristics, including stability. MEDISCA Network Inc. makes no warranties or representations with regard to the functioning or appropriateness of this product in any compounded formulation, which use is solely at the discretion and liability of the practitioner.</i></p>			
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Keep refrigerated (Do not freeze).
	2	Keep out of reach of children.	7	Cap tightly after use.
	3	Shake well before use.	8	May impair mental and/or physical ability. Use care when operating a car or machinery.
	4	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	9	Protect from light.
	5	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.		
Pharmacist Instructions	Add any auxiliary labels specific to the active ingredient to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Spironolactone 5 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 493v6
-------------------	---	-----	-------------

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 167.
2.	Aldactone. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties</i> , 2005: 71.
3.	Propylene Glycol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 521.
4.	Spironolactone. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . London, England: The Pharmaceutical Press; 2005: 1003.
5.	Spironolactone. (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 1562.
6.	Spironolactone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 2nd Edition</i> . American Pharmaceutical Association; 2000: 348.
7.	Spironolactone (Monograph). US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 1596.
8.	USP <795>. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 2053.
9.	Spironolactone. US Pharmacopeial Convention, Inc. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1217.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.